Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue: 2014-2019

Historic Non-Current Deffered Revenue for KalVista Pharmaceuticals (KALV) over the last 4 years, with Apr 2019 value amounting to $3.3 million.

  • KalVista Pharmaceuticals' Non-Current Deffered Revenue fell 31.81% to $2.5 million in Q1 2020 from the same period last year, while for Jan 2020 it was $2.5 million, marking a year-over-year decrease of 31.81%. This contributed to the annual value of $3.3 million for FY2019, which is 69.23% down from last year.
  • KalVista Pharmaceuticals' Non-Current Deffered Revenue amounted to $3.3 million in FY2019, which was down 69.23% from $10.9 million recorded in FY2018.
  • KalVista Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $10.9 million during FY2018, with a 5-year trough of $56,000 in FY2015.
  • For the 2-year period, KalVista Pharmaceuticals' Non-Current Deffered Revenue averaged around $7.1 million, with its median value being $7.1 million (2018).
  • Data for KalVista Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY tumbled of 69.23% (in 2019) over the last 5 years.
  • Yearly analysis of 3 years shows KalVista Pharmaceuticals' Non-Current Deffered Revenue stood at $56,000 in 2015, then reached $10.9 million in 2018, then plummeted by 69.23% to $3.3 million in 2019.